Dizlin Pharmaceuticals has appointed Björn Velin as CEO and he joined the company as of September 1st. Björn Velin has a long and solid experience from the pharmaceutical industry and especially from leading positions in the areas of sales and development of medical drugs for treatment of diseases in the central nervous system.

Björn Velin has worked for more than 25 years at Lundbeck in various roles and most recently as President of Lundbeck in Japan.

“We are pleased to announce the recruitment of Björn Velin as CEO of Dizlin Pharmaceuticals. This appointment marks an important step for the development of our business and the future of the company,” comments Leif Bring, Chairman of the Board.